Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.
“With the successful completion of our initial public offering last month, we are in a strong position to advance our product candidates and invest in our DCE Platform® to bring new compounds into development,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
